Company profile
ACTUATE THERAPEUTICS, INC.
NASDAQ:ACTUBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ELRAGLUSIB | phase2 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04832438 | phase2 | withdrawn | 2030-12-18 | 2033-06-18 | Actuate Therapeutics Inc. | 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma |
| NCT03678883 | phase2 | active_not_recruiting | 2019-01-04 | 2026-06-01 | Actuate Therapeutics Inc. | 9-ING-41 in Patients With Advanced Cancers |
| NCT04239092 | phase1 | terminated | 2020-06-05 | 2025-07-07 | Actuate Therapeutics Inc. | 9-ING-41 in Pediatric Patients With Refractory Malignancies. |
| NCT04218071 | phase2 | completed | 2020-08-20 | 2022-10-13 | Actuate Therapeutics Inc. | Actuate 1901: 9-ING-41 in Myelofibrosis |
| NCT07714395 | phase1_2 | not_yet_recruiting | 2026-10-01 | 2029-07-01 | Actuate Therapeutics Inc. | Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors |
FDA applications (0)
No records yet.